OTCMKTS:VRBCF Virbac (VRBCF) Stock Price, News & Analysis $408.00 0.00 (0.00%) As of 05/18/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock About Virbac Stock (OTCMKTS:VRBCF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Virbac alerts:Sign Up Key Stats Today's Range$408.00▼$408.0050-Day Range$384.75▼$436.3252-Week Range$384.75▼$408.00VolumeN/AAverage Volume100 shsMarket CapitalizationN/AP/E Ratio61.69Dividend Yield0.47%Price TargetN/AConsensus RatingN/A Company Overview Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France. Read More Virbac Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreVRBCF MarketRank™: Virbac scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Virbac. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Virbac is 61.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.65.Price to Earnings Ratio vs. SectorThe P/E ratio of Virbac is 61.69, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.58. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverVirbac has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Virbac has recently increased by 168.40%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldVirbac pays a meaningful dividend of 1.15%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthVirbac does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Virbac is 28.73%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Virbac's dividend. News and Social Media3.1 / 5News SentimentN/A News SentimentVirbac has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Virbac this week, compared to 0 articles on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Virbac insiders have not sold or bought any company stock.Percentage Held by Institutions24.31% of the stock of Virbac is held by institutions.Read more about Virbac's insider trading history. Receive VRBCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virbac and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRBCF Stock News HeadlinesVirbac SA (OTCMKTS:VRBCF) Short Interest UpdateMay 15, 2026 | americanbankingnews.comVirbac : Declaration of the number of shares and voting rights 04/2026May 7, 2026 | globenewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 19 at 1:00 AM | Profits Run (Ad)Virbac : Public release of Virbac Annual Report at 31 December 2025.April 27, 2026 | globenewswire.comVirbac SA (VRBCF) Stock Price, News, Quote & History - Yahoo FinanceApril 25, 2026 | finance.yahoo.comVirbac: strong Q1 2026 growth of +7.7% at CERS, driven by double-digit growth of our priority Supercharge4 platformsApril 16, 2026 | globenewswire.comVirbac : Declaration of the number of shares and voting rights 03/2026April 7, 2026 | globenewswire.comVirbac SA (VRBCF) Q4 2025 Earnings Call TranscriptMarch 18, 2026 | seekingalpha.comSee More Headlines VRBCF Stock Analysis - Frequently Asked Questions How have VRBCF shares performed this year? Virbac's stock was trading at $436.32 at the beginning of the year. Since then, VRBCF stock has decreased by 6.5% and is now trading at $408.00. How do I buy shares of Virbac? Shares of VRBCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:VRBCF Previous SymbolOTC:VRBCF CIK2029969 Webwww.virbac.fr Phone33.4.92.08.71.00FaxN/AEmployees5,459Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio61.69 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:VRBCF) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virbac SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Virbac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.